tetano
Editor, Senior Moderator
Vaccine. 2019 Oct 21. pii: S0264-410X(19)31408-2. doi: 10.1016/j.vaccine.2019.10.035. [Epub ahead of print] [h=1]Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.[/h]
Pebody RG[SUP]1[/SUP], Zhao H[SUP]2[/SUP], Whitaker HJ[SUP]2[/SUP], Ellis J[SUP]2[/SUP], Donati M[SUP]3[/SUP], Zambon M[SUP]2[/SUP], Andrews N[SUP]2[/SUP].
[h=3]Author information[/h] 1 Public Health England National Infection Service, Colindale, London, UK. Electronic address: Richard.Pebody@phe.gov.uk. 2 Public Health England National Infection Service, Colindale, London, UK. 3 Public Health England National Infection Service, Bristol, UK.
[h=3]Abstract[/h] 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged 2-17. The test negative case control approach was used to estimate aVE by influenza A subtype and vaccine type. Cases and controls were selected from a sentinel laboratory surveillance system which collates details of individuals tested for influenza with reverse-transcription polymerase chain reaction (RT-PCR) on respiratory samples. Vaccine and clinical history was obtained from general practitioners of study participants. There were 307 hospitalised cases and 679 hospitalised controls. End-of-season influenza aVE was 53.0% (95% CI: 33.3, 66.8) against influenza confirmed hospitalisation; 63.5% (95% CI: 34.4, 79.7) against influenza A(H1N1)pdm09 hospitalisation and 31.1% (95% CI: -53.9, 69.2) against influenza A(H3N2). LAIV aVE was 49.1% (95% CI: 25.9, 65.0) for any influenza and 70.7% (95% CI: 41.8, 85.3) for A(H1N1)pdm09, whereas for those receiving quadrivalent inactivated influenza vaccine (QIV), aVE was 64.4% (95% CI: 29.4, 82.0) and 44.4% (95% CI: -51.9, 79.6) respectively. We provide evidence of overall significant VE for both LAIV and QIV against influenza associated hospitalisation in children 2-17 years of age, most notably against influenza A(H1N1)pdm09, with non-significant protection against A(H3N2).
Crown Copyright ? 2019. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Children; Hospitalisation; Influenza vaccine effectiveness; LAIV
PMID: 31648914 DOI: 10.1016/j.vaccine.2019.10.035
Pebody RG[SUP]1[/SUP], Zhao H[SUP]2[/SUP], Whitaker HJ[SUP]2[/SUP], Ellis J[SUP]2[/SUP], Donati M[SUP]3[/SUP], Zambon M[SUP]2[/SUP], Andrews N[SUP]2[/SUP].
[h=3]Author information[/h] 1 Public Health England National Infection Service, Colindale, London, UK. Electronic address: Richard.Pebody@phe.gov.uk. 2 Public Health England National Infection Service, Colindale, London, UK. 3 Public Health England National Infection Service, Bristol, UK.
[h=3]Abstract[/h] 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged 2-17. The test negative case control approach was used to estimate aVE by influenza A subtype and vaccine type. Cases and controls were selected from a sentinel laboratory surveillance system which collates details of individuals tested for influenza with reverse-transcription polymerase chain reaction (RT-PCR) on respiratory samples. Vaccine and clinical history was obtained from general practitioners of study participants. There were 307 hospitalised cases and 679 hospitalised controls. End-of-season influenza aVE was 53.0% (95% CI: 33.3, 66.8) against influenza confirmed hospitalisation; 63.5% (95% CI: 34.4, 79.7) against influenza A(H1N1)pdm09 hospitalisation and 31.1% (95% CI: -53.9, 69.2) against influenza A(H3N2). LAIV aVE was 49.1% (95% CI: 25.9, 65.0) for any influenza and 70.7% (95% CI: 41.8, 85.3) for A(H1N1)pdm09, whereas for those receiving quadrivalent inactivated influenza vaccine (QIV), aVE was 64.4% (95% CI: 29.4, 82.0) and 44.4% (95% CI: -51.9, 79.6) respectively. We provide evidence of overall significant VE for both LAIV and QIV against influenza associated hospitalisation in children 2-17 years of age, most notably against influenza A(H1N1)pdm09, with non-significant protection against A(H3N2).
Crown Copyright ? 2019. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Children; Hospitalisation; Influenza vaccine effectiveness; LAIV
PMID: 31648914 DOI: 10.1016/j.vaccine.2019.10.035